News and Trends 10 Apr 2019 Needle-Free Vaccine for Bubonic Plague to be Developed in the UK The UK biotech Enesi Pharma has joined forces with researchers from the University of Oxford to develop a vaccine for the bubonic plague that is simple to use and doesn’t require needles. Caused by the bacteria Yersinia pestis, the bubonic plague is infamous for having killed over 50 million Europeans in the Middle Ages. While […] April 10, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 9 Apr 2019 French First-in-Class Diabetes Drug Nails Phase III Trial An oral first-in-class drug targeting the mitochondria, developed by the French biotech Poxel, has shown big potential for treating type 2 diabetes in a phase III trial in Japan. Poxel’s lead candidate drug imeglimin has taken a step closer to entering the huge market for diabetes type 2 treatments. In a phase III trial in […] April 9, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 8 Apr 2019 AACR 2019: European Biotech Progresses in Fighting Cancer The American Association for Cancer Research (AACR) met up in Atlanta, USA, to showcase the newest advances in cancer treatment from around the world. Sit back as we give you a quick rundown of the most interesting presentations from European organizations working to improve the treatment of cancer. Clinical trials In the conference last […] April 8, 2019 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Startup Scout 5 Apr 2019 This Biotech Is Making Tissue Bioprinting Child’s Play 3D printing living tissues is complex and technically tricky. Based in Gothenburg, Sweden, Cellink is developing bioprinting technology with a focus on making it easy to use for non-experts. Mission: To make bioprinting technology simpler to use for researchers. This could be used to make cancer disease models for drug testing, and even printing […] April 5, 2019 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 3 Apr 2019 UK Scientists Activate Stem Cells to Heal Corneal Injuries A group of researchers in the UK has developed a potential treatment for corneal injuries, such as those caused by chemical burns, by making surrounding tissue softer and letting stem cells regenerate damaged tissue. The cornea is a transparent tissue that is important for focusing light onto the retina and guarding entry into the eye. […] April 3, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 3 Apr 2019 €21M Series A to Finance Belgian Biotech’s Regenerative Antibodies The Belgian biotech AgomAb has raised €21M and partnered with the Dutch biotech argenx to develop antibody treatments that could regenerate damaged tissue. The round was led by the Belgian investor V-Bio Ventures and Advent France Biotechnology. AgomAb will use the big Series A funding to test antibody treatments for fibrosis in clinical trials, as […] April 3, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 2 Apr 2019 Swiss Scientists Make Synthetic Bacterial Genome Using Computers Synthetic biology researchers at ETH Zurich are the first to construct a simplified artificial bacterial genome with the help of computer algorithms, which could lead to better-engineered microorganisms for the production of therapeutics and other chemicals. Back in 2008, US researchers led by the famous biologist John Craig Venter made headlines for synthesizing the genome […] April 2, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 1 Apr 2019 Cambridge Fund Raises €175M to Supercharge Local Life Sciences Ecosystem The UK venture capital fund Cambridge Innovation Capital, backed by the University of Cambridge, has raised €175M (£150M) to spend on life science and technology companies in the Cambridge area. The money will support the 25 companies in the fund’s portfolio, including the biotech Bicycle Therapeutics, whose peptide-toxin molecules are in clinical trials for the […] April 1, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Startup Scout 29 Mar 2019 This Biotech Repurposes Drugs to Fight Huntington’s Disease Barcelona-based SOM Biotech is developing treatments for incurable diseases such as Huntington’s disease with drugs that are already on the market for other diseases. Mission: To repurpose commercially available drugs for the treatment of neurological diseases lacking effective treatments. Using existing drugs to treat these rare, orphan diseases lets the company get the treatments to […] March 29, 2019 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 28 Mar 2019 Gene Therapy Exceeds Expectations in Treating Children’s Neurological Disease A gene therapy developed by the UK company Orchard Therapeutics has greatly improved the motor symptoms of children with an incurable neurological disease. The 20 children in the phase II trial suffered from metachromatic leukodystrophy, a rare genetic disease caused by the mutation of a protein that breaks down sulfur-containing molecules in cells. This leads […] March 28, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 28 Mar 2019 Swiss Biotech Raises €20M to Develop Decoy Drugs in Autoimmune Disease The biotech Polyneuron has raised a Series A round of €20.1M (CHF 22.5M) to start human testing with a treatment for a rare autoimmune disease. Based in Basel, Polyneuron is developing drugs to treat anti-MAG peripheral neuropathy. This debilitating disease is caused by the immune system producing autoantibodies that attack nerve support cells, which stops […] March 28, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 27 Mar 2019 Artificial Intelligence Could Beat Tumors Resistant to Immunotherapy The French company OSE Immunotherapeutics has signed a partnership to use artificial intelligence to develop treatments for tumors that don’t respond to checkpoint inhibitor drugs. In the last five years, checkpoint inhibitor drugs have become a potentially life-saving option for people that don’t respond to traditional cancer treatments. These antibody drugs have shown promise in […] March 27, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email